Table 1.
Blood eosinophils cut-off as predictor of airways eosinophilia.
| Asthma populations | B-EOS cut-off (μl) | S-EOS cut-off (%) | Sensitivity (%) | Specificity (%) |
|---|---|---|---|---|
| Unselected (30) | >220 | ≥3% | 77 | 70 |
| Mild-to-severe asthma (31) | >270 | ≥3% | 78 | 91 |
| Mild to severe (SARP) (32) | >300 | >2% | 59 | 65 |
| Uncontrolled asthmatics (33) | 1.5% of WBC | ≥ 2.5% | 61.5 | 78.3 |
| Uncontrolled asthmatics (34) | 2.7% of WBC | ≥3% | 92.2 | 75.8 |
| Poorly controlled with high-dose ICS (Reslizumab trial) (37) | >400 | >3% | ||
| Severe eosinophilic asthma (DREAM trial) | ≥300 | ≥3% | ||
| Severe eosinophilic asthma (MENSA, MUSCA trials) | >150 | - | ||
| Severe uncontrolled asthma (38) | >300 (ELEN Index*) | ≥2% | ||
| Severe eosinophilic asthma (SIROCCO,CALIMA trials) | ≥300 | - |
*Mathematically weighted ratios of three blood cell populations, Eosinophils/Lymphocytes and Eosinophils/Neutrophils (ELEN), as predictor variables of sputum eosinophilia.